this piece corresponds to the legacy myPDB login in the form of a bootstrap modal, will likely retire-->

Chemical Component Summary

NameZOLEDRONIC ACID
Identifiers(1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid
FormulaC5 H10 N2 O7 P2
Molecular Weight272.09 g/mol
TypeNON-POLYMER
Isomeric SMILESOC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O
InChIInChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
InChIKeyXRASPMIURGNCCH-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count26
Chiral Atom Count0
Chiral Atomsn/a
Bond Count26
Aromatic Bond Count5
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00399 Stereoisomeric match
NameZoledronic acid
Groupsapproved
DescriptionZoledronate (zoledronic acid, marketed by Novartis under the trade names Zometa and Reclast) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronate is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.
Synonyms
  • (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
  • (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
  • Anhydrous Zoledronic Acid
  • Zol
  • Zoledronate
Salts
  • Zoledronate disodium
  • Zoledronate trisodium
  • Zoledronic acid hemipentahydrate
  • Zoledronic acid monohydrate
Brand Names
  • Aclasta
  • Act Zoledronic Acid
  • Act Zoledronic Acid Concentrate
  • PMS-zoledronic Acid
  • Reclast
Affected OrganismHumans and other mammals
IndicationFor the treatment of hypercalcemia of malignancy. Also for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. In May of 2007, the drug was approved for treatment of Paget’s Disease.
PharmacologyZoledronate is a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronate is used to prevent osteoporosis and skeletal fractures, particularly in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia, particularly hypercalcemia of malignancy. It can also be helpful for treating pain from bone metastases.
Mechanism of actionThe action of zoledronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Zoledronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates such as zoledronate appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Route of administration
  • Intravenous
Categories
  • Azoles
  • Bone Density Conservation Agents
  • Chemical Actions and Uses
  • Diphosphonates
  • Drugs Affecting Bone Structure and Mineralization
ATC-Code
  • M05BB08
  • M05BA08
AHFS-Code92:00.00
CAS number118072-93-8
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682